RDHL

Redhill Biopharma

--(--)

Market Open: --

--(--)

Post-Market: --

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About RDHL

Redhill Biopharma Ltd.

A specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases

Industry

Pharmaceutical

Established Date

08/03/2009

Listing Date

12/26/2012

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.redhillbio.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

21 Ha’arba’a Street, Tel Aviv 6473921, Israel

Business

Introduction

Redhill Biopharma Ltd., was incorporated in Israel on August 3, 2009. The company is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases. The company's primary objective is to become a leading specialty biopharmaceutical company through its commercial presence in the United States, supporting the commercialization of existing and potential other products marketed in the United States, as well as the commercialization of possible future therapeutic candidates, if approved. The company is currently focusing on the commercialization of GI-related products Talicia (omeprazole, amoxicillin and rifabutin) and Aemcolo (rifamycin) in the United States.

Company Financials

EPS

RDHL has released its 2023 Q2 earnings. EPS was reported at 0.09, versus the expected 0.00, beating expectations. The chart below visualizes how RDHL has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

RDHL has released its 2023 Q2 earnings report, with revenue of 1.80M, reflecting a YoY change of -90.21%, and net profit of 761.00K, showing a YoY change of 106.50%. The Sankey diagram below clearly presents RDHL’s revenue sources and cost distribution.